UroGen Pharma (NASDAQ:URGN) Trading Up 3.6% – Should You Buy?

UroGen Pharma Ltd. (NASDAQ:URGN)’s share price traded up 3.6% during mid-day trading on Thursday . The company traded as high as $12.06 and last traded at $12.09. 285,917 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 497,520 shares. The stock had previously closed at $11.66.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock. HC Wainwright decreased their price target on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. Finally, D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, March 10th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $38.20.

UroGen Pharma Price Performance

The firm has a market capitalization of $559.12 million, a price-to-earnings ratio of -3.85 and a beta of 1.12. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The company’s fifty day moving average is $10.54 and its two-hundred day moving average is $11.59.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. Equities research analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares of the company’s stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Several institutional investors and hedge funds have recently modified their holdings of URGN. KLP Kapitalforvaltning AS bought a new position in UroGen Pharma in the fourth quarter valued at approximately $59,000. Lazard Asset Management LLC acquired a new stake in shares of UroGen Pharma during the fourth quarter worth $67,000. BNP Paribas Financial Markets lifted its position in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in UroGen Pharma in the 4th quarter worth $101,000. Finally, Oppenheimer & Co. Inc. bought a new position in UroGen Pharma during the 4th quarter worth about $126,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.